You are here
Articles
Posted on Monday, January 30, 2012 - 4:46pm
Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Jorge Cortes, January 2012
Posted on Wednesday, January 25, 2012 - 2:39pm
Purpose:
We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular...
Posted on Tuesday, January 24, 2012 - 12:33am
Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases,...
Posted on Sunday, January 22, 2012 - 2:31pm
Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.
Posted on Monday, January 16, 2012 - 1:43pm
CML Support Group: Response to the Appeal Panel judgement in favour of the NICE
decision not to recommend dasatinib as a second line treatment option for imatinib
resistant CML and in...
Posted on Sunday, January 15, 2012 - 12:49pm
Guidance: Patient version
Dasatinib, high-dose imatinib and nilotinib for chronic myeloid leukaemia:
This document is about when dasatinib, high-...
Posted on Friday, January 13, 2012 - 3:12pm
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
Posted on Tuesday, January 10, 2012 - 8:14pm
CML—The Changing Landscape of Front-line Therapy:
Interview With Dr. Jane Apperley
Posted on Tuesday, January 10, 2012 - 8:03pm
Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Posted on Friday, January 6, 2012 - 12:20pm
Given the imminent publication by NICE of their draft appraisal document for dasatinib, nilotinib and imatinib in 1st line use, I thought it a good idea to update you all on CMLSg's campaigning activities during the...
Posted on Wednesday, January 4, 2012 - 5:08pm
University of Pennsylvania (Penn State) researchers Sandeep Prahbu and Rober Paulson with interest in Leukaemia studied a compound called D12-PGJ3 derived from fish oil which targeted and killed CML stem cells in mice...
Posted on Wednesday, December 21, 2011 - 2:33pm
Subcutaneous Omacetaxine Effective in Chronic- or Accelerated-Phase CML Resistant to 2 or More TKIs Including Imatinib
Posting Date: December 19, 2011
Post hoc analysis of 2 open-label, multicenter, single-arm, phase II...
Posted on Wednesday, December 21, 2011 - 2:26pm
Bosutinib Active in Patients With Philadelphia Chromosome–Positive Leukemia Resistant to Second-Generation TKIs
Posting Date: December 13, 2011
Nonrandomized, multicenter, open-label, phase I/II trial
Summary...
Posted on Saturday, December 10, 2011 - 11:41am
Posted on Wednesday, December 7, 2011 - 7:04pm
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 30, S Freeman
- ‹ previous
- 16 of 29
- next ›